• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病患者的脂肪细胞因子和细胞角蛋白-18:CHA 指数的引入。

Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.

机构信息

Department of Medicine, Second Medical Clinic, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Greece.

出版信息

Ann Hepatol. 2013 Sep-Oct;12(5):749-57.

PMID:24067262
Abstract

BACKGROUND AND RATIONALE

Insulin resistance (IR), adipocytokines, oxidative stress and hepatic apoptosis play a pathogenetic role in nonalcoholic fatty liver disease (NAFLD).

AIMS

The evaluation of specific adipocytokines and markers of IR, oxidative stress and apoptosis in NAFLD patients; the introduction of a combined non-invasive index for nonalcoholic steatohepatitis (NASH).

MATERIAL AND METHODS

Thirty patients with biopsy-proven NAFLD (15 with simple nonalcoholic fatty liver [NAFL], 15 with NASH) and 24 controls were recruited. Blood samples for total and high molecular weight (HMW) adiponectin, visfatin and tumor necrosis factor (TNF)-α, the apoptotic by-product cytokeratin (CK)-18, the reactive oxygen metabolites (ROMs) and standard biochemical tests were measured. Homeostatic model of assessment - insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI) were calculated.

MAIN RESULTS

Total and HMW adiponectin were significantly lower and TNF-α higher in either NAFL or NASH group compared to control group; CK-18 was significantly higher in NASH compared to either NAFL or control group. CHAI (an acronym of CK-18, HOMA-IR, AST Index) was calculated as the product of parameters being significantly different between NAFL and NASH groups. CHAI was significantly higher in NASH (24.2 [15.1-214.0]) compared to either NAFL (15.7 [6.8-22.7]) or control (5.1 [2.4-7.6]) group (p < 0.001) and significantly higher as the severity of steatosis, fibrosis, ballooning, lobular and portal inflammation advanced.

CONCLUSION

CHAI was escalating from controls to NAFL and NASH and was higher by increasing the severity of all the main histological lesions. However, a validation study is needed before introducing CHAI in clinical practice.

摘要

背景与理由

胰岛素抵抗(IR)、脂肪细胞因子、氧化应激和肝凋亡在非酒精性脂肪性肝病(NAFLD)中起致病作用。

目的

评估 NAFLD 患者中特定的脂肪细胞因子以及 IR、氧化应激和凋亡的标志物;引入一种非酒精性脂肪性肝炎(NASH)的非侵入性综合指数。

材料与方法

招募了 30 名经活检证实的 NAFLD 患者(15 名单纯非酒精性脂肪肝 [NAFL],15 名 NASH)和 24 名对照组。测量了全分子质量(HMW)和高分子质量(HMW) adiponectin、内脏脂肪素和肿瘤坏死因子(TNF)-α、凋亡副产物细胞角蛋白(CK)-18、活性氧代谢物(ROMs)以及标准生化测试的血液样本。计算了稳态模型评估的胰岛素抵抗(HOMA-IR)和定量胰岛素敏感指数检查(QUICKI)。

主要结果

无论是在 NAFL 组还是 NASH 组,总 adiponectin 和 HMW adiponectin 均显著低于对照组,TNF-α显著高于对照组;CK-18 在 NASH 组显著高于 NAFL 组或对照组。CHAI(CK-18、HOMA-IR、AST 指数的缩写)的计算方法是在 NAFL 和 NASH 组之间有显著差异的参数的乘积。NASH 组的 CHAI(24.2[15.1-214.0])明显高于 NAFL 组(15.7[6.8-22.7])或对照组(5.1[2.4-7.6])(p<0.001),随着脂肪变性、纤维化、气球样变、肝小叶和门脉炎症的严重程度的增加而升高。

结论

CHAI 从对照组到 NAFL 和 NASH 逐渐升高,随着所有主要组织学病变严重程度的增加而升高。然而,在将 CHAI 引入临床实践之前,需要进行验证研究。

相似文献

1
Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.非酒精性脂肪性肝病患者的脂肪细胞因子和细胞角蛋白-18:CHA 指数的引入。
Ann Hepatol. 2013 Sep-Oct;12(5):749-57.
2
Irisin in patients with nonalcoholic fatty liver disease.非酒精性脂肪性肝病患者的鸢尾素。
Metabolism. 2014 Feb;63(2):207-17. doi: 10.1016/j.metabol.2013.09.013. Epub 2013 Oct 18.
3
Serum homocysteine levels in patients with nonalcoholic fatty liver disease.非酒精性脂肪性肝病患者的血清同型半胱氨酸水平。
Ann Hepatol. 2012 Jan-Feb;11(1):68-76.
4
Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease.血浆内脂素与非酒精性脂肪性肝病的肝及全身炎症的相关性。
Ann Hepatol. 2013 Jul-Aug;12(4):548-55.
5
Adipokines and cytokines in non-alcoholic fatty liver disease.非酒精性脂肪性肝病中的脂肪因子和细胞因子
Aliment Pharmacol Ther. 2008 Mar 1;27(5):412-21. doi: 10.1111/j.1365-2036.2007.03586.x. Epub 2007 Dec 10.
6
A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH).一种用于肥胖相关非酒精性脂肪性肝炎(NASH)的新型诊断生物标志物组合。
Obes Surg. 2008 Nov;18(11):1430-7. doi: 10.1007/s11695-008-9506-y. Epub 2008 May 24.
7
A Simple Index for Nonalcoholic Steatohepatitis-HUFA-Based on Routinely Performed Blood Tests.一种基于常规血液检测的非酒精性脂肪性肝炎简单指数-HUFA。
Medicina (Kaunas). 2019 Jun 3;55(6):243. doi: 10.3390/medicina55060243.
8
Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.血浆细胞角蛋白 18 作为非酒精性脂肪性肝病患者非酒精性脂肪性肝炎和纤维化的生物标志物的价值有限。
J Hepatol. 2014 Jan;60(1):167-74. doi: 10.1016/j.jhep.2013.07.042. Epub 2013 Aug 20.
9
Apoptotic and anti-apoptotic seromarkers for assessment of disease severity of non-alcoholic steatohepatitis.用于评估非酒精性脂肪性肝炎疾病严重程度的凋亡和抗凋亡血清标志物。
Arab J Gastroenterol. 2014 Mar;15(1):6-11. doi: 10.1016/j.ajg.2014.01.009. Epub 2014 Feb 7.
10
The clinical significance of insulin resistance in non-diabetic patients with early forms of non-alcoholic fatty liver disease.胰岛素抵抗在非酒精性脂肪性肝病早期非糖尿病患者中的临床意义。
Ter Arkh. 2018 Aug 27;90(8):63-68. doi: 10.26442/terarkh201890863-68.

引用本文的文献

1
Association of circulating visfatin level and metabolic fatty liver disease: An updated meta-analysis and systematic review.循环内脂素水平与代谢性脂肪性肝病的相关性:一项更新的荟萃分析和系统评价。
Medicine (Baltimore). 2024 Sep 13;103(37):e39613. doi: 10.1097/MD.0000000000039613.
2
Nonalcoholic fatty liver disease test: an external validation cohort.非酒精性脂肪性肝病检测:外部验证队列。
Hormones (Athens). 2024 Mar;23(1):131-136. doi: 10.1007/s42000-023-00502-1. Epub 2023 Nov 13.
3
Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?
非酒精性脂肪性肝病中的脂肪因子:我们正朝着新的生物标志物和治疗靶点迈进吗?
Biology (Basel). 2022 Aug 19;11(8):1237. doi: 10.3390/biology11081237.
4
Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis.脂毒性是导致非酒精性脂肪性肝炎的主要原因。
Int J Mol Sci. 2022 May 5;23(9):5146. doi: 10.3390/ijms23095146.
5
Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis.非酒精性脂肪性肝病和肝纤维化患者的血清内脂素水平:系统评价与Meta分析
J Clin Med. 2021 Jul 7;10(14):3029. doi: 10.3390/jcm10143029.
6
Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy.靶向代谢相关脂肪性肝病(MAFLD)中程序性细胞死亡:一种有前途的新疗法。
Cell Mol Biol Lett. 2021 May 7;26(1):17. doi: 10.1186/s11658-021-00254-z.
7
Effect of glucagon-like peptide-1 receptor agonists on adipokine level of nonalcoholic fatty liver disease in rats fed high-fat diet.胰高血糖素样肽-1受体激动剂对高脂饮食喂养大鼠非酒精性脂肪性肝病脂肪因子水平的影响
Open Med (Wars). 2020 Jul 18;15(1):689-696. doi: 10.1515/med-2020-0212. eCollection 2020.
8
NAD metabolism: pathophysiologic mechanisms and therapeutic potential.NAD 代谢:病理生理机制与治疗潜力。
Signal Transduct Target Ther. 2020 Oct 7;5(1):227. doi: 10.1038/s41392-020-00311-7.
9
Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD.靶向分析三个激素系统,鉴定与 NAFLD 的存在和严重程度相关的分子。
J Clin Endocrinol Metab. 2020 Mar 1;105(3):e390-400. doi: 10.1210/clinem/dgz172.
10
Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease.脂肪因子与非酒精性脂肪性肝病发生发展的关系
Endocrinol Metab (Seoul). 2018 Mar;33(1):33-43. doi: 10.3803/EnM.2018.33.1.33.